OncoMatch/Clinical Trials/NCT06585527
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Is NCT06585527 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TS-2021 for glioblastoma multiforme.
Treatment: TS-2021 — The goal of this clinical trial is to evaluate the safety and efficacy of oncolytic virus TS-2021 in the treatment of recurrent malignant glioma.About 30 eligible participants with recurrent malignant glioma will : * Be intratumoral injected the TS-2021 oncolytic virus to study its safety and efficacy. * Be followed for 1 year after the injection to complete imaging studies, neurological function tests, and report adverse events. Using the data obtained during the follow-up period, researchers will conduct statistical analyses and evaluate the safety and efficacy of oncolytic virus TS-2021.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Grade: high-grade
The patient had a recurrence of supratentorial high-grade glioma.
Prior therapy
Must have received: surgery — initial
After the initial surgery, the imaging showed that the tumor was completely removed, followed by conventional radiotherapy or (and) chemotherapy
Must have received: radiotherapy — initial
followed by conventional radiotherapy or (and) chemotherapy
Must have received: chemotherapy — initial
followed by conventional radiotherapy or (and) chemotherapy
Lab requirements
Blood counts
neutrophil absolute value ≥ 1,500/mm3, hemoglobin ≥10 g/dl, platelet count ≥100,000/mm3
Kidney function
serum creatinine ≤1.5×uln
Liver function
total bilirubin level ≤1.5×uln, glutamic pyruvic transaminase/glutamic oxalacetic transaminase ≤ 2.5× uln
Cardiac function
the heart function was normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify